Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,161.02 +16.89 (+0.21%) Bitcoin USD
57,656.51 -5,767.18 (-9.09%) CMC Crypto 200
1,242.85 -96.21 (-7.19%)
GSK Jan 2026 60.000 call
| Previous close | 0.4000 |
| Open | 0.6000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 60.00 |
| Expiry date | 2026-01-16 |
| Day's range | 0.4000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ReutersGSK raises profit forecast, says sales growth to slow in H2
CEO Emma Walmsley's strategy has focussed on vaccines and infectious diseases and a shift in its HIV focus to long-acting treatment and prevention therapies. It expects a rise in 2024 sales in the upper end of its 5% to 7% forecast range. It also attributed its increased forecast to a successful royalty dispute appeal for ovary cancer drug Zejula in the first quarter.
Insider Monkey20 Fastest Growing Health Tech Companies in the World
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 Fastest Growing Health tech Companies in the World. Explosive Growth and Key Trends in the Digital […]
- Reuters
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.
